[ad_1]
Due to increased tobacco consumption, India contributes to nearly 60% of head and neck cancer – inside the mouth, nose and throat – all over the world. The number is expected to double by 2030, health experts said Saturday.
"The global contribution of patients with head and neck cancer is 57.5% in India, of which 80 000 are cases of oral cancer each year" , said Kumar Prabhash of Tata Memorial Hospital in Mumbai.
"Tobacco is one of the leading causes of these cases of head and neck cancers. And we estimate the number of cases to double by 2030, "added Sumit Goyal of the Department of Medical Oncology at Rajiv Gandhi Cancer Institute in New Delhi.
In a clinical study, recently presented to the Annual conference of the American Society of Clinical Oncologists (ASCO), in Chicago, Prabhash experts have concluded that a molecule called Nimotuzumab badociated with chemo-radiotherapy could be a better effective treatment against cancers of the Nimotuzumab is the first biological product of indigenous origin developed by Biocon, a biotransporter from Bangalore, introduced in India as BIOMAb EGFR for head and neck cancer in 2006. [19659003] To examine its efficacy, 536 head and neck cancers patients aged 18 to 80. The results showed that patients who had been administered cisplatin-mediated nimotuzumab (used to chemotherapy) and radiotherapy survived almost three times more than those who received only chemotherapy and radiotherapy. It also reduced the risk of disease progression by 26%.
Biomab has a unique bivalent binding, because of which it binds primarily to the site of cancer cells where overexpression of the EGFR protein occurs. This is important since this mechanism of action of Biomab ensures that only cancer cells are destroyed, unlike other targeted agents, ensuring that it does not cause additional toxicity, explains Prabhash. .
The clinical study proves the introduction of this molecule. He added that standard treatment of patients with head and neck cancer significantly improves treatment outcomes on factors such as progression-free survival, disease-free survival, locoregional control duration, and overall survival. .
Although no serious side effects have been observed, it has led to a slight increase in the level of mucositis – an inflammation of the mouth that is considered a common effect after cancer treatment, he noted. Although BIOMAb EGFR is currently approved for the treatment of head and neck cancers in India, Cuba, Argentina, Colombia, Côte d 'Ivoire, Gabon, Ukraine, Peru, Vietnam and in Sri Lanka, several clinical trials are underway. this molecule in various other indications also like lung cancer, pancreatic cancer, uterine cervix cancer.
Follow @htlifeandstyle for more information
[ad_2]
Source link
